Danisco - Cambridge Antibody Technology

Genencor International was acquired by Danisco A/S in April 2005.  Following the acquisition, Danisco A/S made the decision to spin-out Genencor’s health care assets, which were focused on oncology therapeutics. 

Cambridge Antibody Technology was a UK based biopharmaceutical company focused on developing human monoclonal antibody therapeutics.  With the acquisition of Genencor’s health care assets, CAT established its first US operation.

Burrill & Company’s Role

The Merchant Banking Group served as the exclusive advisor for Danisco A/S in its divestiture of Genencor’s health care assets (which included a team of people and pre-clinical and clinical stage programs)

In the spin out, Burrill & Company pursued parallel venture capital and M&A paths. 

The time between the initiation of the engagement and the close of the transaction with CAT was 6 months.